Cargando…
Promotion of Cell Death in Cisplatin-Resistant Ovarian Cancer Cells through KDM1B-DCLRE1B Modulation
Ovarian cancer is the gynecological malignancy with the poorest prognosis, in part due to its high incidence of recurrence. Platinum agents are widely used as a first-line treatment against ovarian cancer. Recurrent tumors, however, frequently demonstrate acquired chemo-resistance to platinum agent...
Autores principales: | Lee, Yeon Kyu, Lim, Jinyeong, Yoon, So Young, Joo, Jong Cheon, Park, Soo Jung, Park, Yoon Jung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566920/ https://www.ncbi.nlm.nih.gov/pubmed/31108893 http://dx.doi.org/10.3390/ijms20102443 |
Ejemplares similares
-
Anti-cancer effect of Scutellaria baicalensis in combination with cisplatin in human ovarian cancer cell
por: Choi, Bo Yoon, et al.
Publicado: (2017) -
NK Cells from RAG- or DCLRE1C-Deficient Patients Inhibit HCMV
por: Wu, Zeguang, et al.
Publicado: (2019) -
Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis
por: Yoo, Jung, et al.
Publicado: (2022) -
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway
por: Kim, Haeun, et al.
Publicado: (2020) -
DCLRE1B promotes tumor progression and predicts immunotherapy response through METTL3-mediated m6A modification in pancreatic cancer
por: Li, Lincheng, et al.
Publicado: (2023)